ISAL 2023 | Management & outcome of patients with CBF AML and FLT3-ITD
Mark Levis
• 21 Mar 2023
Mark Levis, MD, PhD, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, outlines the key findings from a study evaluating the prognostic impact of FLT3-ITD in patients with core-binding factor (CBF) acute myeloid leukemia (AML). The findings suggested that the co-occurrence of these mutations is associated with worse outcomes, and this subset of patients should be treated with allogeneic transplantation. This interview took place at the 18th International Symposium on Acute Leukemias (ISAL XVIII), held in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
